跳至主要内容
临床试验/NCT01942629
NCT01942629Unknown不适用

Prognostic Value of Quantitative p63 Immunostaining in Adenocarcinoma of Lung, Breast, and Pancreas

Rambam Health Care Campus0 个研究点目标入组 300 人开始时间: 2013年10月最近更新:
适应症

试验速览

阶段
不适用
入组人数
300
主要终点
5 year overall survival

研究概览

简要总结

The p63 gene is a recently discovered member of the p53 family located at chromosome 3q27Many studies have reported that overexpression of p63 can mimic p53 activities by binding DNA, activating transcription, and inducing apoptosis.

Various studies proved p63 as a marker of basal cells in normal salivary glands, breast, prostate, respiratory and squamous epithelia, and of tumor cells from various malignancies. Still, p63 has been the subject of relatively few studies in lung adenocarcinoma, and breast carcinoma, and no study has described the correlation of p63 with pancreatic ductal adenocarcinoma.

In the current study, we aim to evaluate the prognostic value of the expression of p63 in the lung adenocarcinoma, breast adenocarcinoma, and pancreatic ductal adenocarcinoma. We will achieve this aim by collecting clinical data retrospectively from the patients' medical records as well as assessing the histological sections and performing immunohistochemical staining for p63.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients who were treated at our institution for lung adenocarcinoma, breast adenocarcinoma, or pancreatic ductal adenocarcinoma.
  • Available histopathological diagnosis of the malignancy.

排除标准

  • Patients with inoperable tumors.
  • Patients with second primary tumor.
  • Patients with pathological blocks not enough for future slicing.

结局指标

主要结局

5 year overall survival

时间窗: 5 years

if the patient is alive or dead 5 years following the treatment

次要结局

  • recurrence free survival(5 years)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

SHOROOK NA'ARA MD

MD

Rambam Health Care Campus

相似试验